search
Back to results

Sham Controlled Clinical Trial of Renal Denervation in Patients With Resistant Hypertension

Primary Purpose

Hypertension

Status
Completed
Phase
Not Applicable
Locations
Australia
Study Type
Interventional
Intervention
Renal Denervation
Sham control
Sponsored by
Baker Heart and Diabetes Institute
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Hypertension focused on measuring Renal denervation, Blood pressure, Cardiovascular risk, Target organ damage, Sympathetic activity, Non-compliance

Eligibility Criteria

18 Years - 85 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • systolic office BP ≥140mmHg and ambulatory day time average ≥135mmHg despite concurrent treatment with ≥3 anti-hypertensive drugs

Exclusion Criteria:

  • renal artery anatomy ineligible for treatment
  • eGFR <15mL/min/1.73m2 (using MDRD calculation)
  • myocardial infarction, unstable angina or cerebrovascular accident within 3 months of screening visit
  • life expectancy of <12 months
  • female participants of childbearing potential must have negative pregnancy test prior to treatment

Sites / Locations

  • Baker IDI Heart & Diabetes Institute

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Sham Comparator

Arm Label

Renal Denervation

Sham control

Arm Description

participants randomised to undergo renal denervation

participants randomised to undergo sham procedure

Outcomes

Primary Outcome Measures

Change in ambulatory systolic blood pressure between groups
Difference in mean ambulatory systolic daytime blood pressure between RDN group and sham-control group at 6 month follow up.

Secondary Outcome Measures

Change in mean 24h systolic blood pressure between groups
Change in mean 24h systolic blood pressure between RDN group and sham-control group at 6 month follow up.
Change in mean night time systolic blood pressure between groups
Change in mean night time systolic blood pressure between RDN group and sham-control group at 6 month follow up.
Change in mean office systolic blood pressure between groups
Change in mean office systolic blood pressure between RDN group and sham-control group at 6 month follow up.

Full Information

First Posted
May 12, 2015
Last Updated
September 13, 2023
Sponsor
Baker Heart and Diabetes Institute
search

1. Study Identification

Unique Protocol Identification Number
NCT02444442
Brief Title
Sham Controlled Clinical Trial of Renal Denervation in Patients With Resistant Hypertension
Official Title
The Australian SHAM Controlled Clinical Trial of Renal DeNervation in Patients With Resistant Hypertension (AUSHAM-RDN-01)
Study Type
Interventional

2. Study Status

Record Verification Date
September 2023
Overall Recruitment Status
Completed
Study Start Date
June 2015 (undefined)
Primary Completion Date
April 2020 (Actual)
Study Completion Date
April 2020 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Baker Heart and Diabetes Institute

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
The purpose of this study is to assess the efficacy of catheter-based renal denervation in reducing blood pressure in patients with resistant hypertension compared to a sham procedure. Patients will be randomized to RDN or sham control in a 2:1 ratio. All participants will be switched to a single pill triple combination treatment prior to the procedure. A total of 105 patients will be recruited into the study, 70 patients in the RDN arm and 35 patients in the sham control arm. The duration of this study is 36 months.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hypertension
Keywords
Renal denervation, Blood pressure, Cardiovascular risk, Target organ damage, Sympathetic activity, Non-compliance

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
105 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Renal Denervation
Arm Type
Active Comparator
Arm Description
participants randomised to undergo renal denervation
Arm Title
Sham control
Arm Type
Sham Comparator
Arm Description
participants randomised to undergo sham procedure
Intervention Type
Device
Intervention Name(s)
Renal Denervation
Intervention Description
Deliberate disruption of the renal nerves via radio frequency energy delivery to renal arteries.
Intervention Type
Other
Intervention Name(s)
Sham control
Intervention Description
Arterial access only. No delivery of radio frequency energy to renal arteries.
Primary Outcome Measure Information:
Title
Change in ambulatory systolic blood pressure between groups
Description
Difference in mean ambulatory systolic daytime blood pressure between RDN group and sham-control group at 6 month follow up.
Time Frame
6 months post procedure
Secondary Outcome Measure Information:
Title
Change in mean 24h systolic blood pressure between groups
Description
Change in mean 24h systolic blood pressure between RDN group and sham-control group at 6 month follow up.
Time Frame
6 months post procedure
Title
Change in mean night time systolic blood pressure between groups
Description
Change in mean night time systolic blood pressure between RDN group and sham-control group at 6 month follow up.
Time Frame
6 months post procedure
Title
Change in mean office systolic blood pressure between groups
Description
Change in mean office systolic blood pressure between RDN group and sham-control group at 6 month follow up.
Time Frame
6 months post procedure
Other Pre-specified Outcome Measures:
Title
Change in percentage of patients achieving BP target between groups
Description
Change in percentage of patients achieving BP target between groups
Time Frame
6 months post procedure
Title
Change in percentage of patients with an ambulatory systolic BP reduction ≥5mmHg between groups
Description
Change in percentage of patients with an ambulatory systolic BP reduction ≥5mmHg between groups
Time Frame
6 months post procedure
Title
Change in percentage of patients with an office systolic BP reduction ≥10mmHg between groups
Description
Change in percentage of patients with an office systolic BP reduction ≥10mmHg between groups
Time Frame
6 months post procedure
Title
Change of sympathetic nerve activity between groups
Description
Change of sympathetic nerve activity (MSNA, renal and whole body NE spillover) between groups
Time Frame
6 months post procedure
Title
Change in left ventricular function between groups
Description
Change in left ventricular function (LV mass index, ejection fraction, diastolic filling) between groups
Time Frame
6 months post procedure
Title
Change in Serum Biochemistry between groups
Description
Plasma Renin Activity, aldosterone levels, estimated Glomerular Filtration Rate(eGFR), inflammatory markers, fasting glucose, fasting insulin, C-peptide, Homeostasis Model Assessment (HOMA) index, Lipid profile between groups
Time Frame
6 months post procedure
Title
Change in Urine Biochemistry between groups
Description
Urinary albumin creatinine ratio (UACR), 24 hour urinary creatinine clearance, sodium between groups
Time Frame
6 months post procedure
Title
Change in Quality of Life between groups
Description
Change in Quality of life as assessed by relevant questionnaires between groups
Time Frame
6 months post procedure
Title
Change in cognitive function between groups
Description
Change in cognitive function as assessed by relevant questionnaires and assessment tools between groups
Time Frame
6 months post procedure
Title
Change in microRNA expression between groups
Description
Change in microRNA expression as assessed by relevant assays between groups
Time Frame
6 months post procedure

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
85 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: systolic office BP ≥140mmHg and ambulatory day time average ≥135mmHg despite concurrent treatment with ≥3 anti-hypertensive drugs Exclusion Criteria: renal artery anatomy ineligible for treatment eGFR <15mL/min/1.73m2 (using MDRD calculation) myocardial infarction, unstable angina or cerebrovascular accident within 3 months of screening visit life expectancy of <12 months female participants of childbearing potential must have negative pregnancy test prior to treatment
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Markus P Schlaich, Professor
Organizational Affiliation
Laboratory Head, Neurovascular Hypertension and Kidney Disease (Baker IDI)
Official's Role
Principal Investigator
Facility Information:
Facility Name
Baker IDI Heart & Diabetes Institute
City
Melbourne
State/Province
Victoria
ZIP/Postal Code
3004
Country
Australia

12. IPD Sharing Statement

Citations:
PubMed Identifier
34806762
Citation
Pisano A, Iannone LF, Leo A, Russo E, Coppolino G, Bolignano D. Renal denervation for resistant hypertension. Cochrane Database Syst Rev. 2021 Nov 22;11(11):CD011499. doi: 10.1002/14651858.CD011499.pub3.
Results Reference
derived

Learn more about this trial

Sham Controlled Clinical Trial of Renal Denervation in Patients With Resistant Hypertension

We'll reach out to this number within 24 hrs